107 related articles for article (PubMed ID: 18835163)
1. Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
Guay D; Boulet L; Friesen RW; Girard M; Hamel P; Huang Z; Laliberté F; Laliberté S; Mancini JA; Muise E; Pon D; Styhler A
Bioorg Med Chem Lett; 2008 Oct; 18(20):5554-8. PubMed ID: 18835163
[TBL] [Abstract][Full Text] [Related]
2. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
[TBL] [Abstract][Full Text] [Related]
3. Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.
Hamblin JN; Angell TD; Ballantine SP; Cook CM; Cooper AW; Dawson J; Delves CJ; Jones PS; Lindvall M; Lucas FS; Mitchell CJ; Neu MY; Ranshaw LE; Solanke YE; Somers DO; Wiseman JO
Bioorg Med Chem Lett; 2008 Jul; 18(14):4237-41. PubMed ID: 18539455
[TBL] [Abstract][Full Text] [Related]
4. Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity.
Li Y; Liang J; Siu T; Hu E; Rossi MA; Barnett SF; Defeo-Jones D; Jones RE; Robinson RG; Leander K; Huber HE; Mittal S; Cosford N; Prasit P
Bioorg Med Chem Lett; 2009 Feb; 19(3):834-6. PubMed ID: 19097777
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
[TBL] [Abstract][Full Text] [Related]
6. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
Kameda M; Kobayashi K; Ito H; Miyazoe H; Tsujino T; Nakama C; Kawamoto H; Ando M; Ito S; Suzuki T; Kanno T; Tanaka T; Tahara Y; Tani T; Tanaka S; Tokita S; Sato N
Bioorg Med Chem Lett; 2009 Aug; 19(15):4325-9. PubMed ID: 19487123
[TBL] [Abstract][Full Text] [Related]
7. The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity.
Siu T; Li Y; Nagasawa J; Liang J; Tehrani L; Chua P; Jones RE; Defeo-Jones D; Barnett SF; Robinson RG
Bioorg Med Chem Lett; 2008 Jul; 18(14):4191-4. PubMed ID: 18550373
[TBL] [Abstract][Full Text] [Related]
8. Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.
Berglund S; Egner BJ; Gradén H; Gradén J; Morgan DG; Inghardt T; Giordanetto F
Bioorg Med Chem Lett; 2009 Aug; 19(15):4274-9. PubMed ID: 19500982
[TBL] [Abstract][Full Text] [Related]
9. 2,4-Diaminopyridine delta-opioid receptor agonists and their associated hERG pharmacology.
Owen DR; Rodriguez-Lens M; Corless MD; Gaulier SM; Horne VA; Kinloch RA; Maw GN; Pearce DW; Rees H; Ringer TJ; Ryckmans T; Stammen BL
Bioorg Med Chem Lett; 2009 Mar; 19(6):1702-6. PubMed ID: 19231185
[TBL] [Abstract][Full Text] [Related]
10. Optimization of 2-piperidin-4-yl-acetamides as melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Designing out hERG inhibition.
Berglund S; Egner BJ; Gradén H; Gradén J; Morgan DG; Inghardt T; Giordanetto F
Bioorg Med Chem Lett; 2009 Aug; 19(15):4268-73. PubMed ID: 19500979
[TBL] [Abstract][Full Text] [Related]
11. 3-amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile.
Scott DA; Bell KJ; Campbell CT; Cook DJ; Dakin LA; Del Valle DJ; Drew L; Gero TW; Hattersley MM; Omer CA; Tyurin B; Zheng X
Bioorg Med Chem Lett; 2009 Feb; 19(3):701-5. PubMed ID: 19114305
[TBL] [Abstract][Full Text] [Related]
12. Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR.
Mitchell CJ; Ballantine SP; Coe DM; Cook CM; Delves CJ; Dowle MD; Edlin CD; Hamblin JN; Holman S; Johnson MR; Jones PS; Keeling SE; Kranz M; Lindvall M; Lucas FS; Neu M; Solanke YE; Somers DO; Trivedi NA; Wiseman JO
Bioorg Med Chem Lett; 2010 Oct; 20(19):5803-6. PubMed ID: 20732811
[TBL] [Abstract][Full Text] [Related]
13. Aminoquinazolines as TRPV1 antagonists: modulation of drug-like properties through the exploration of 2-position substitution.
Blum CA; Zheng X; Brielmann H; Hodgetts KJ; Bakthavatchalam R; Chandrasekhar J; Krause JE; Cortright D; Matson D; Crandall M; Ngo CK; Fung L; Day M; Kershaw M; De Lombaert S; Chenard BL
Bioorg Med Chem Lett; 2008 Aug; 18(16):4573-7. PubMed ID: 18662872
[TBL] [Abstract][Full Text] [Related]
14. Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
Coon T; Moree WJ; Li B; Yu J; Zamani-Kord S; Malany S; Santos MA; Hernandez LM; Petroski RE; Sun A; Wen J; Sullivan S; Haelewyn J; Hedrick M; Hoare SJ; Bradbury MJ; Crowe PD; Beaton G
Bioorg Med Chem Lett; 2009 Aug; 19(15):4380-4. PubMed ID: 19553115
[TBL] [Abstract][Full Text] [Related]
15. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.
Sasaki T; Takahashi T; Nagase T; Mizutani T; Ito S; Mitobe Y; Miyamoto Y; Kanesaka M; Yoshimoto R; Tanaka T; Takenaga N; Tokita S; Sato N
Bioorg Med Chem Lett; 2009 Aug; 19(15):4232-6. PubMed ID: 19520574
[TBL] [Abstract][Full Text] [Related]
17. Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.
Packard GK; Papa P; Riggs JR; Erdman P; Tehrani L; Robinson D; Harris R; Shevlin G; Perrin-Ninkovic S; Hilgraf R; McCarrick MA; Tran T; Fleming Y; Bai A; Richardson S; Katz J; Tang Y; Leisten J; Moghaddam M; Cathers B; Zhu D; Sakata S
Bioorg Med Chem Lett; 2012 Jan; 22(1):747-52. PubMed ID: 22137342
[TBL] [Abstract][Full Text] [Related]
18. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO
Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678
[TBL] [Abstract][Full Text] [Related]
19. Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
Goto T; Shiina A; Yoshino T; Mizukami K; Hirahara K; Suzuki O; Sogawa Y; Takahashi T; Mikkaichi T; Nakao N; Takahashi M; Hasegawa M; Sasaki S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3325-8. PubMed ID: 23602400
[TBL] [Abstract][Full Text] [Related]
20. ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.
Kobayashi M; Kubo S; Iwata M; Ohtsu Y; Takahashi K; Shimizu Y
Int Immunopharmacol; 2011 Jun; 11(6):732-9. PubMed ID: 21315169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
